1. Home
  2. RIGL vs OPRX Comparison

RIGL vs OPRX Comparison

Compare RIGL & OPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RIGL
  • OPRX
  • Stock Information
  • Founded
  • RIGL 1996
  • OPRX 2006
  • Country
  • RIGL United States
  • OPRX United States
  • Employees
  • RIGL N/A
  • OPRX N/A
  • Industry
  • RIGL Biotechnology: Pharmaceutical Preparations
  • OPRX Business Services
  • Sector
  • RIGL Health Care
  • OPRX Consumer Discretionary
  • Exchange
  • RIGL Nasdaq
  • OPRX Nasdaq
  • Market Cap
  • RIGL 335.5M
  • OPRX 380.6M
  • IPO Year
  • RIGL 2000
  • OPRX N/A
  • Fundamental
  • Price
  • RIGL $30.17
  • OPRX $17.55
  • Analyst Decision
  • RIGL Buy
  • OPRX Buy
  • Analyst Count
  • RIGL 5
  • OPRX 8
  • Target Price
  • RIGL $38.20
  • OPRX $11.81
  • AVG Volume (30 Days)
  • RIGL 668.8K
  • OPRX 374.6K
  • Earning Date
  • RIGL 11-06-2025
  • OPRX 11-12-2025
  • Dividend Yield
  • RIGL N/A
  • OPRX N/A
  • EPS Growth
  • RIGL N/A
  • OPRX N/A
  • EPS
  • RIGL 5.43
  • OPRX N/A
  • Revenue
  • RIGL $267,921,000.00
  • OPRX $104,748,000.00
  • Revenue This Year
  • RIGL $59.93
  • OPRX $17.92
  • Revenue Next Year
  • RIGL N/A
  • OPRX $10.91
  • P/E Ratio
  • RIGL $5.32
  • OPRX N/A
  • Revenue Growth
  • RIGL 105.62
  • OPRX 25.89
  • 52 Week Low
  • RIGL $13.57
  • OPRX $3.78
  • 52 Week High
  • RIGL $43.72
  • OPRX $20.70
  • Technical
  • Relative Strength Index (RSI)
  • RIGL 39.94
  • OPRX 47.24
  • Support Level
  • RIGL $27.75
  • OPRX $17.24
  • Resistance Level
  • RIGL $29.46
  • OPRX $18.93
  • Average True Range (ATR)
  • RIGL 1.49
  • OPRX 1.19
  • MACD
  • RIGL -0.41
  • OPRX -0.25
  • Stochastic Oscillator
  • RIGL 25.90
  • OPRX 9.66

About RIGL Rigel Pharmaceuticals Inc.

Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.

About OPRX OptimizeRx Corporation

OptimizeRx Corp is engaged in the healthcare market in the United States. It provides digital health messaging via electronic health records, providing a direct channel for pharmaceutical companies to communicate with healthcare providers and patients. The cloud-based solution supports patient adherence to medications by providing real-time access to financial assistance, prior authorization, education, and clinical information. Its product offerings are Financial Messaging, Brand and Clinical Messaging, Brand Support, and Patient Engagement.

Share on Social Networks: